Novo Nordisk Threatens to End 340B Pricing Over In-House Claims Data Policy

Novo Nordisk building
Novo Nordisk recently sent a letter warning certain 340B providers that failure to submit claims data could result in the loss of 340B pricing.
Novo Nordisk recently warned certain 340B covered entities that they could lose access to 340B pricing if they do not [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »

Cassidy’s 340B Proposal Draws Stakeholder Criticism, Praise 

Cassidy in a hearing
340B stakeholders offered varying reactions to U.S. Sen. Bill Cassidy's (R-La.) 340B draft discussion proposal.
340B stakeholders recently offered mixed reactions to a key—but outgoing—Republican U.S. senator’s sweeping proposal that would allow drug manufacturer 340B [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »

Fed. Judge Lets Most State Claims Proceed in 340B Insulin Antitrust Suit

U.S. District Court for the Western District of New York
The U.S. District Court for the Western District of New York recently allowed the majority of two health centers’ state antitrust claims to proceed against four diabetes drug manufacturers.
A New York federal judge recently kept most of two health centers’ state 340B antitrust claims alive against four insulin [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »

BMS Exempts WA From In-House Claims Data Reqs, CP Restrictions

BMS logo sign
Bristol Myers Squibb said its 340B contract pharmacy restrictions and in-house pharmacy claims data requirements no longer apply to Washington state covered entities.
A New Jersey-based drugmaker recently announced that its 340B contract pharmacy restrictions and in-house pharmacy claims data requirements no longer [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »

340B Research Roundup: Health Affairs Scholar Study, ADAP White Paper, Op-Eds

Recent 340B program research and commentary included a Health Affairs Scholar study, an ADAP Advocacy white paper and a pair of op-eds.
Editor’s Note: As the 340B program draws increased attention from researchers, policymakers and commentators, 340B Report has launched a new [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »
Industry Insights Logo

340B Beyond the Headlines – Policy, Compliance, and Legislative Impact

SPONSORED CONTENT

Verity Solutions is pleased to host a thought-provoking panel discussion ahead of the 340B Coalition Summer Conference, bringing together expert voices in 340B policy, compliance, and operations for a timely discussion on the

Read More »

340B Report Promotes William Newton to Editor-in-Chief, Shannon Young to Managing Editor

Will and Shannon headshots
William Newton (left) and Shannon Young (right) have been promoted to 340B Report's editor-in-chief and managing editor, respectively.

340B Report announced today that William Newton has been promoted to editor-in-chief and Shannon Young has been promoted to managing editor, strengthening the news service’s editorial leadership as it continues to grow as the indispensable source of independent, comprehensive

Read More »

Breaking News

Sen. Cassidy Releases Sweeping 340B Reform Bill Draft

Sen. Bill Cassidy
U.S. Sen. Bill Cassidy (R-La.) today released a sweeping 340B reform discussion draft.
U.S. Sen. Bill Cassidy (R-La.) released sweeping 340B draft legislation Thursday morning that would allow drug manufacturers to offer 340B [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »

340B Health, Hospitals Seek to Defend HRSA in AbbVie Patient Definition Suit

D.C. District Court exterior.
340B Health and two health systems have asked a federal judge for permission to join HRSA in defending the agency’s 340B patient definition against drugmaker AbbVie’s lawsuit.
A hospital trade group and two health systems have asked a federal judge for permission to join HRSA in defending [...]

Please Login or Become a Paid Subscriber to View this Content

Read More »
Industry Insights Logo

Turning 340B Covered Entity (CE) Volatility Into a Strategic Advantage

SPONSORED CONTENT

2026 has already proven to be an incredibly turbulent year for 340B. As new state and federal regulations continue to take effect, many organizations may find their current 340B designation no longer accurately

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live